Loading…
← CockpitCompetitor Analysis › 7459.T MEDIPAL HOLDINGS CorporationOpen in the cockpit ↗

MEDIPAL HOLDINGS Corporation7459.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Distributors

One of Japan's largest pharmaceutical wholesalers, distributing drugs from manufacturers to hospitals and pharmacies.

≈ Japan's McKessonMomentum leader 87
Mkt cap
$3.70B
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$10.2M
20-day average traded
Fwd P/E
12.5×
forward earnings
ROIC−WACC
+1.8 pp
WACC 5.0%
Hurdle
-11 pp
Req g minus delivered
Next earnings
77 days
3 Feb 2027
Close · JPY¥3,234
1D-0.7%
1W+2.9%
1M+3.9%
3M+14.4%
6M+15.1%
YTD+16.8%
1Y+27.4%
ATR %3.0%
52w lowhigh10.4% off high

What MEDIPAL does

One of Japan's largest pharmaceutical wholesalers, distributing drugs from manufacturers to hospitals and pharmacies.

Buys drugs from makers and resells them to hospitals and pharmacies for a thin markup, so profit depends on volume, delivery efficiency and payment terms more than on price. Reimbursement prices are set by the government and cut regularly, which squeezes wholesale margins. It is one of the handful of national-scale wholesalers.

In one line: Japan's McKesson.

Products and services

  • Pharmaceutical wholesale distribution
  • Medical device distribution
  • Pharmacy support services

Customers

  • Hospitals
  • Pharmacies
  • Clinics

Where it sits in the supply chain

  • Health care
  • Pharmaceutical distribution
  • Wholesale distribution of drugs and…

What could go right

  • Drug volume growth from aging population

What could go wrong

  • Thin distribution margins
  • Drug price revisions by government

Moat: narrow (scale, distribution, regulatory licence). Nationwide licensed distribution network and scale purchasing in a low-margin, logistics-heavy business.

Headquarters: Tokyo, Japan · Founded: 1948 · Employees: 13,024

Named competitors

MEDIPAL at a glance

Size MEDIPAL (7459.T) is a Japan Health Care company (Medical Distributors) with a market value of $3.70B, the 317th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,234 on 18 Nov 2026.

Performance Over six months the shares gained 15.1%, against +7.6% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 3.9% over the last twelve months (peer median +6.2%); the operating margin is 1.4% (peer median 3.2%).

Valuation It trades at 12.5× forward earnings against a peer median of 15.9× (4th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.8 points above its cost of capital (5.0% WACC).

Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 20267459.T 115Peer median 107
Six months, rebased to 100: MEDIPAL against the median of its 20 peers (local-currency closes).

MEDIPAL financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥3.89T¥3.82T¥3.67T¥3.56T¥3.36T
Revenue growth—+4%+3%+6%—
Gross profit¥248B¥247B¥242B¥233B¥212B
EBITDA¥80.8B¥71.8B¥74.0B¥65.3B¥63.6B
Net income¥43.5B¥42.5B¥40.3B¥41.5B¥38.8B
Free cash flown/a¥42.8B¥51.7B¥46.3B¥5.66B
Capital expendituren/a¥9.69B¥12.4B¥19.4B¥13.5B
Total debt¥190B¥4.40B¥4.17B¥1.46B¥7.38B

Quarterly statements and history in the cockpit →

MEDIPAL competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%-10%0%+10%600998AMP33492784ASKER008930GALE9987DKSH1099RDCHSIC33606005877476DOCM3015846007136033687459.T6-month return →1-month return →
Up and to the right = strong over both horizons. MEDIPAL is the large dot.

Fundamentals: revenue growth against valuation

0%+5%+10%10×20×600998AMP33492784ASKERGALE9987DKSH10998129HSIC336060058774766033687459.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. MEDIPAL is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%600998AMP2784ASKER008930GALE9987DKSH8129HSIC33603015847459.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. MEDIPAL is the large dot.

MEDIPAL competitors and peer comparison

Head to head with its named competitors (7459.T vs 2784.T vs 9987.T vs 8129.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
MEDIPAL 7459.T$3.70B+15%+4%1%12.5×-7.2%
Alfresa 2784.T$2.81B-3%+4%1%18.4×-8.4%
Suzuken 9987.T$2.36B+8%+5%1%15.8×-10.4%
Toho 8129.T$1.64B-5%+4%1%22.2×-4.6%

How MEDIPAL compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

MEDIPAL against its 20 peers (data as of 18 Nov 2026)
Measure7459.TPeer medianRank in peer set
1-month return+3.9%+1.3%7th highest of 21
6-month return+15.1%+7.6%8th highest of 21
Distance from 52-week high-10.4%-15.8%7th highest of 21
Revenue growth (TTM)+3.9%+6.2%6th lowest of 21
Operating margin1.4%3.2%6th lowest of 21
Forward P/E12.5×15.9×4th cheapest of 16
Growth the price implies (Req g, 7 yrs)-7.2%-2.0%6th least demanding of 17
Growth delivered (Del g)+3.5%+5.7%5th lowest of 17
Hurdle (Req g minus delivered)-10.7 pp-8.1 pp7th least demanding of 17
ROIC minus cost of capital+1.8 pp+1.6 pp10th highest of 21
Net debt / EBITDA-1.0×0.9×6th least indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
MEDIPAL 7459.TJapan$3.70B+15%+4%1%12.5×-7.2%+3.5%
Jointown Pharmaceutical 600998.SSChina$3.99B+7%+9%2%11.8×0.2%+7.8%
Amplifon AMP.MIItaly$3.39B+8%0%10%17.0×6.8%+9.8%
COSMOS Pharmaceutical 3349.TJapan$3.21B+2%+9%4%15.9×n/an/a
Alfresa 2784.TJapan$2.81B-3%+4%1%18.4×-8.4%+3.5%
Asker Healthcare ASKER.STSweden$2.69B-14%+12%7%24.8×4.7%+12.7%
Hanmi Science 008930.KSSouth Korea$2.58B+48%+6%4%n/a26.0%+9.6%
Galenica GALE.SWSwitzerland$5.31B+8%+6%5%23.9×7.0%+3.5%
Suzuken 9987.TJapan$2.36B+8%+5%1%15.8×-10.4%+3.2%
DKSH DKSH.SWSwitzerland$5.99B+24%-1%3%21.8×-1.2%+0.6%
Sinopharm 1099.HKHong Kong$6.74B0%+3%3%6.2×-7.3%+4.0%
Toho 8129.TJapan$1.64B-5%+4%1%22.2×-4.6%+5.1%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%n/an/an/a
Henry Schein HSICUnited States$9.47B+17%+6%6%14.7×10.2%+5.4%
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%14.6×-14.5%+7.6%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%13.4×-6.9%+1.2%
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%n/a-2.7%+17.9%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%n/an/an/a
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%9.5×-9.7%+6.0%

Questions

Who are MEDIPAL's main competitors?
Named competitors: Alfresa Holdings (2784.T), Suzuken (9987.T), Toho Holdings (8129.T). The cockpit's measured peer set (industry) also includes Jointown Pharmaceutical (600998.SS), Amplifon (AMP.MI), COSMOS Pharmaceutical (3349.T), Alfresa (2784.T), Asker Healthcare (ASKER.ST), Hanmi Science (008930.KS).
Is MEDIPAL expensive compared with its peers?
On forward p/e it trades at 12.5× against a peer median of 15.9×, 4th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has MEDIPAL stock performed?
Over six months to 18 Nov 2026 the shares returned +15.1% against +7.6% for the median peer; over one year +27.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.